![](/img/cover-not-exists.png)
PCN44 COST COMPARISON OF ERLOTINIB VERSUS PEMETREXED FOR THE FIRST-LINE MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN SPAIN
J Castro de Carpeño, AJ Castro-Gómez, S Walzer, J RayVolume:
13
Year:
2010
Language:
english
DOI:
10.1016/s1098-3015(11)71940-4
File:
PDF, 79 KB
english, 2010